Company profile: Lexaria Bioscience
1.1 - Company Overview
Company description
- Provider of patented DehydraTECH technology that improves bio-absorption, reduces onset time, and enhances delivery of lipophilic drugs across the blood-brain barrier; out-licenses this platform and operates units focused on pharmaceuticals (hypertension, antiviral, epilepsy), oral non-combusted nicotine, hemp-derived ingredients, a Health Canada licensed lab for cannabinoid and other formulations, and nutraceutical CPG applications.
Products and services
- DehydraTECH: Patent-protected drug-delivery system engineers lipophilic payload formulations, boosting bio-absorption, reducing onset time, enabling blood–brain barrier transport, and supporting healthier administration with lower dosing
- Lexaria Nicotine LLC: Industrial-grade R&D investigates DehydraTECH-enabled oral non-combusted nicotine product formats, improving bio-absorption and reducing onset time for ingestible nicotine to promote healthier administration methods
- Lexaria Pharmaceutical Corp.: Pharmaceutical-grade programs architect DehydraTECH applications for drugs targeting hypertension, antiviral treatments, and epilepsy, aiming healthier administration, lower overall dosing, and higher effectiveness of ingestible molecules
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Lexaria Bioscience
Alexza
HQ: United States
Website
- Description: Provider of inhaled therapeutics for acute and intermittent conditions, featuring commercial ADASUVE (loxapine) for acute agitation in adults with schizophrenia or bipolar disorder, and developing Staccato inhalation candidates: alprazolam for epileptic seizures, apomorphine for OFF episodes in Parkinson’s disease, and granisetron for cyclic vomiting syndrome.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alexza company profile →
Corsair Pharma
HQ: United States
Website
- Description: Provider of a transdermal treprostinil prodrug patch for pulmonary arterial hypertension (PAH), designed to deliver consistent blood levels and reduce the need for invasive administration. Develops transformative solutions to improve the therapeutic profile of medications and provide superior treatment for patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Corsair Pharma company profile →
Nu-Med Plus
HQ: United States
Website
- Description: Provider of patented medical device technology to safely deliver precision doses of nitric oxide.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nu-Med Plus company profile →
Valeritas
HQ: United States
Website
- Description: Provider of innovative drug delivery solutions for Type 2 diabetes, including V-GO, a disposable insulin pump, and a micro needle patch, leveraging h-Patch technology to improve clinical and humanistic outcomes for patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Valeritas company profile →
Acorda Therapeutics
HQ: United States
Website
- Description: Provider of commercial-stage biopharmaceutical therapies, identifying, developing and commercializing therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other nervous system disorders. Products include INBRIJA (levodopa inhalation powder for Parkinson’s symptoms), AMPYRA (dalfampridine to improve walking in adults with MS), and the ARCUS drug delivery platform.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Acorda Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Lexaria Bioscience
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Lexaria Bioscience
2.2 - Growth funds investing in similar companies to Lexaria Bioscience
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Lexaria Bioscience
4.2 - Public trading comparable groups for Lexaria Bioscience
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →